Bifidobacterium longum affects the methylation level of forkhead box P3 promoter in 2, 4, 6-trinitrobenzenesulphonic acid induced colitis in rats
Bifidobacterium longum affects the methylation level of forkhead box P3 promoter in 2, 4, 6-trinitrobenzenesulphonic acid induced colitis in rats
复制标题
DOI：
10.1016/j.micpath.2017.07.029
复制
发表时间：
2017-09-01
影响因子：
3.8
通讯作者：
Zou, Xiaoping
中科院分区：
文献类型：
--
作者：
Zhang, Ming;Zhou, Lixing;Zou, Xiaoping
长双歧杆菌 (B. Longum) 是一种常见的益生菌，定植于人体肠道中，可对抗炎症性肠病 (IBD) 等慢性炎症的发展。但其根本机制仍不清楚。本研究的目的是评估长双歧杆菌对叉头盒 P3 (Foxp3) 启动子甲基化水平的影响。分别用长双歧杆菌或培养基治疗2,4,6-三硝基苯磺酸(TNBS)诱导的结肠炎大鼠模型。提取脾外周血单核细胞(PBMC)细胞的基因组DNA。经过亚硫酸氢盐处理和焦磷酸测序后，分析了叉头盒蛋白 P3 (Foxp3) 启动子中每个 CpG 位点的甲基化水平。 B. Longum 治疗改变了 TNBS 治疗的结肠炎大鼠中 Foxp3 启动子的甲基化水平，并显着使 Foxp3 启动子中的几个 CpG 位点去甲基化。 Foxp3 启动子的去甲基化可能与 B. Longum 治疗 IBD 的有效性有关。仍有必要进一步研究 B. Longum 在 Foxp3 去甲基化中的作用。使用长双歧杆菌或其代谢产物是进一步研究 IBD 潜在治疗方法的一种选择。 (C) 2017 年由爱思唯尔有限公司出版。
Bifidobacterium longum (B. Longum) is a common probiotic colonized in the human gut and against the development of chronic inflammation including inflammatory bowel disease (IBD). But the underlying mechanism remains unknown. The aim of this study was to evaluate the affection of B. longum on the methylation levels of forkhead box P3 (Foxp3) promoter. 2, 4, 6-trinitrobenzenesulphonic acid (TNBS)induced colitis rat models were treated with B. longum or medium, respectively. The genomic DNA of spleen peripheral blood mononuclear cells (PBMC) cells was extracted. After bisulphite treatment and pyrosequencing, the methylation levels of each CpG sites in the promoter of forkhead box protein P3 (Foxp3) were analyzed. B. Longum treatment changes the methylation level in Foxp3 promoter in TNBS-treated colitis rats, and significantly demethylates several CpG sites in Foxp3 promoter. The demethylation of Foxp3 promoter might be involved in the effectiveness of B. Longum treatment for IBD. Further research remains necessary to investigate the role of B. Longum in Foxp3 demethylation. Using B. Longum or its metabolic products is an option for further investigations on potential treatments for IBD. (C) 2017 Published by Elsevier Ltd.